Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 4 Multivariable analysis of relevant clinical and laboratory parameters on event-free and overall survival

From: LDH and hemoglobin outperform systemic inflammatory indices as prognostic factors in patients with soft tissue sarcoma undergoing neoadjuvant treatment

  

EFS

OS

Factor

Strata

Sig.

Hazard Ratio (95%CI)

Sig.

Hazard Ratio (95%CI)

Age (years)

< 62 vs. ≥62

0.53

1.26 (0.61–2.60)

0.58

1.32 (0.49–3.57)

Disease status

Primary vs. recurrent

0.66

1.33 (0.38–4.72)

-

-

Radiologic response (RECIST)

PR/SD vs. PD

0.19

0.54 (0.22–1.36)

0.0068

0.27 (0.10–0.70)

Resection margins

R0 vs. R1-RX

0.025

0.34 (0.14–0.88)

-

-

Albumin (mg/dl)

< 4.1 vs. ≥4.1

0.51

0.76 (0.34–1.71)

-

-

LDH (U/l)

< 213 vs. ≥213

0.0044

0.29 (0.13–0.68)

0.010

0.23 (0.07–0.70)

NLR

< 3.7 vs. ≥3.7

0.88

0.95 (0.46–1.96)

0.15

0.46 (0.16–1.34)

Hemoglobin (g/dl)

< 13.0 Vs. ≥13.0

0.018

2.51 (1.17–5.38)

0.030

2.78 (1.11–6.97)

  1. LDH = Lactate dehydrogenase, NLR = Neutrophil-to-lymphocyte ratio, PR = partial response, SD = Stable disease, PD = Progressive disease, RECIST = Response Evaluation Criteria in Solid Tumors
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us